Key insights: Continue Reading SAN DIEGO, Jan. 22, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released episode 55 of its Science Bytes podcast, featuring Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine. With decades of experience in blood banking and immunohematology, Mullens shares insights into the pressures on today's blood supply and the importance of consistent donor engagement. With expertise spanning clinical ...

Core Viewpoint - QuidelOrtho Corporation will report its financial results for Q4 and full year 2025 on February 11, 2026, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call starting at 2:00 p.m. PT / 5:00 p.m. ET [2] - Interested parties can access the call via the Company's website or by phone using specific dial-in numbers [2] Conference Call Replay - A replay of the conference call will be available shortly after the event on the Company's website [3] Company Overview - QuidelOrtho Corporation is a leading global provider of diagnostic solutions, focusing on advancing fast, accurate, and reliable results to improve patient outcomes [4] - The company has expertise in clinical chemistry, immunoassay, immunohematology, and molecular testing [4]

Core Insights - QuidelOrtho Corporation is at the forefront of in vitro diagnostics, focusing on innovative solutions that enhance patient care [1][7] - The latest podcast episode discusses transformative diagnostic technologies that are reshaping patient management and outcomes [2][3] Diagnostic Innovations - High-sensitivity troponin testing is enabling faster diagnosis and treatment for cardiac patients, improving care efficiency [5] - Non-invasive assays are being developed to enhance gastrointestinal health, reducing the need for invasive procedures [5] - Rapid combination tests are assisting clinicians in effectively managing respiratory surges, streamlining patient care [5] - Advances in molecular diagnostics, informatics, and artificial intelligence are facilitating more personalized and smarter healthcare solutions [5] Research and Development - QuidelOrtho's R&D strategies are focused on addressing global healthcare challenges through innovative diagnostic solutions [5][7] - Collaboration and cutting-edge research are key drivers behind the diagnostic breakthroughs that empower clinicians worldwide [3]

Company Overview - QuidelOrtho Corporation is a leading provider of diagnostic testing solutions with a global footprint and a diversified product portfolio [5] - The company focuses on innovation in diagnostic technologies and expanding access to rapid and accurate testing for both professional and consumer markets [6] - QuidelOrtho generates revenue through direct sales and distribution of diagnostic equipment and consumables to various healthcare providers and laboratories [9] Financial Performance - As of September 30, QuidelOrtho reported a revenue of $2.7 billion and a net income of -$1.2 billion [4] - The company's shares were priced at $27.76, reflecting a 26% decline over the past year, underperforming the S&P 500, which increased by 13% during the same period [3] - The latest quarter showed signs of stabilization in core business, with non-respiratory revenue and lab revenue both growing by 5% [10] Investment Insights - Newtyn Management increased its stake in QuidelOrtho by purchasing 994,332 shares for approximately $30.4 million, raising its total position to 2.7 million shares valued at $79.5 million [2][3] - QuidelOrtho's adjusted EBITDA margin expanded to 25%, up 180 basis points from the previous year, indicating improved cost efficiencies [10] - The company has seen nearly a 90% decline in share value since 2020, but recent operational improvements may suggest a more durable growth trajectory [10][11]

Group 1 - The stock reaction after the third quarter was surprising, with a steep sell-off followed by a notable bounce back [2] - There were insider purchases observed, which were positively received by the market [2] - Feedback from investors post-quarter indicated some pushback regarding the company's performance [2]

Financial Data and Key Metrics Changes - The company reported total revenue growth of 5% for the quarter, excluding COVID and donor screening revenue, indicating solid performance above expectations [15][10] - Adjusted Free Cash Flow guidance for the full year is expected to be 25%-30% of Adjusted EBITDA, with a strong Q4 anticipated due to delayed cash receipts from Q3 [10][11] - The leverage ratio at the end of Q3 was 4.4, which is considered too high, with a target range of 2.5-3.5 times expected by early 2027 [72][73] Business Line Data and Key Metrics Changes - The Labs business grew by 4% in Q3, with immunohematology growing at 5% and Triage at 7%, indicating a stable mid-single digit growth trajectory [15][16] - The immunohematology business holds the number one market position globally, achieving 5% growth in Q3, although Q4 growth is expected to be lower due to shipment timing [34][35] - The Point-of-Care business, particularly Triage, is expected to grow at a high single-digit rate, driven by improved cost management and market competitiveness [43][44] Market Data and Key Metrics Changes - The Chinese market is expected to grow at a mid-single digit rate for the full year 2025, with the company feeling optimistic about opportunities despite previous reimbursement issues [29][33] - The company has been less affected by Chinese government actions aimed at cost reduction compared to competitors, primarily due to its focus on routine chemistry [28][31] Company Strategy and Development Direction - The company aims to increase its integrated analyzer base from 30% to around 50%, which is expected to enhance margins by 10-20 basis points annually [22][23] - The exit from the U.S. donor screening market is projected to reduce revenue headwinds from 2-3 points this year to about 1 point next year, with margin accretion expected post-exit [40][41] - The company is focused on continuous improvement in staffing rather than large-scale cuts, aiming for a more stable operational environment [66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single digit growth in the Labs and immunohematology segments, with a stable revenue base [68] - The approval of the high-sensitivity troponin assay is seen as a confidence booster for maintaining growth in the Labs business [26] - The company anticipates that the LEX acquisition will likely be dilutive in 2026 but expects to reverse this trend by 2027 [70][69] Other Important Information - The company has achieved $140 million in cost savings since mid-2024, primarily through staffing reductions and indirect procurement initiatives [65] - The company is monitoring the impact of COVID revenue decline, which is expected to decrease by about $100 million year-over-year [44] Q&A Session Summary Question: Feedback from investors post-Q3 earnings - Management noted that the stock reaction was perplexing, attributed to high short interest, put option exposure, tax loss selling, and cash flow timing issues related to ERP conversions [6][10] Question: Cash flow guidance and visibility - The company is tracking towards its cash flow guidance of 25%-30% of Adjusted EBITDA, with expectations for a strong Q4 due to cash collection delays [10][12] Question: Growth drivers in the Labs business - The Labs business is expected to maintain a mid-single digit growth trajectory, supported by consistent win rates and integrated analyzer strategy [16][18] Question: Competitive dynamics in China - The company has been less impacted by reimbursement actions in China and expects mid-single digit growth in the market moving forward [28][29] Question: Margin improvement initiatives - The company is targeting 100-200 basis points of margin improvement in 2026, contingent on continued mid-single digit growth in the base business [66][70]

Financial Data and Key Metrics Changes - The company is tracking towards an Adjusted Free Cash Flow guidance of 25%-30% of Adjusted EBITDA for the full year, despite a hiccup in Q3 due to system conversion delays [10][11] - The long-term target for cash flow is to reach 50% of Adjusted EBITDA by 2027, with expected progress in 2026 [11] - Total revenue growth, excluding COVID and donor screening revenue, was reported at 5% for the quarter and year-to-date [15][16] Business Line Data and Key Metrics Changes - The Labs business grew at 4% in constant currency, while Immunohematology and Triage grew at 5% and 7% respectively, indicating solid performance across the base business [15][16] - The immunoassay to integrated analyzer ratio has improved from 25% to 30%, with a target of reaching 50% in the future, which is expected to enhance margins [22][23] Market Data and Key Metrics Changes - The Chinese market is expected to grow at a mid-single digit rate for the full year 2025, with the company feeling optimistic about opportunities despite previous reimbursement issues [29][32] - The immunohematology business holds the number one market position globally, with a growth rate of 5% in Q3, although Q4 growth may be lower due to shipment timing [33] Company Strategy and Development Direction - The company is focusing on optimizing its portfolio by exiting the U.S. donor screening market, which is expected to improve margins once fully wound down [39][40] - The strategy includes enhancing the integrated analyzer base to drive higher-margin immunoassay revenue, with a long runway for growth in this area [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single digit growth in the Labs and Immunohematology segments, with expectations for stable performance in the face of market challenges [15][16][29] - The company anticipates a good Q4 and is optimistic about the overall market dynamics, particularly in China and the point-of-care segment [29][41] Other Important Information - The company has achieved $140 million in cost savings since mid-2024, primarily through staffing reductions and indirect procurement initiatives [62] - The leverage ratio at the end of Q3 was reported at 4.4, with a target to reduce it to 2.5-3.5 times by early 2027 [70][71] Q&A Session Summary Question: Feedback from investors post-Q3 earnings call - Management noted that the stock reaction was perplexing, attributing it to high short interest, put option exposure, and cash flow timing issues related to ERP conversions [7][10] Question: Cash flow guidance and visibility - The company confirmed that cash flow guidance remains unchanged, with expectations for a strong Q4 as cash receipts from Q3 are collected [10][12] Question: Growth drivers in the Labs business - The Labs business is expected to maintain a mid-single digit growth trajectory, supported by consistent win rates and a stable contract structure [16][18] Question: Competitive dynamics in China - Management indicated that the company has been less affected by Chinese government actions compared to competitors, expecting mid-single digit growth in the Chinese market [28][32] Question: Margin improvement initiatives - The company is targeting 100-200 basis points of margin improvement in 2026, contingent on continued mid-single digit growth in the base business [62][65] Question: Future of the LEX acquisition - The company expects to complete the acquisition of LEX following FDA approval, with a limited commercial rollout anticipated in the first half of 2026 [51][56]

QuidelOrtho FY Conference Summary Company Overview - **Company**: QuidelOrtho (NasdaqGS: QDEL) - **Industry**: Life Science Diagnostics and Medical Devices Key Points Performance and Financials - QuidelOrtho achieved approximately **1% organic growth** excluding COVID-related revenues, while the industry is experiencing mid-single digit growth [3][4] - The company reported a **19.5% adjusted EBITDA margin** last year, which is expected to increase to **22% this year** due to successful margin improvement initiatives [4] - Cost reductions of about **$140 million** have been realized since mid-2024, contributing to margin improvements [4] Revenue Headwinds - The shutdown of the U.S. donor screening business is expected to create a **2-3 point headwind** on total reported revenue for the year [6] - COVID-related revenues are declining, contributing an additional **2-3 point headwind** [7][10] - Excluding these impacts, the base business is growing at **4-5%**, driven by solid growth in Labs, Immunohematology, and Triage businesses [8][9] China Market Insights - China accounts for about **11% of total revenues**, with a year-to-date growth of **2.5%** expected to reach mid-single digits for the full year [12] - QuidelOrtho has largely avoided the impacts of VBP and DRG due to its use of dry slide technology and focus on routine chemistry [12][13] Pricing Dynamics - Pricing in the legacy Quidel business remains stable, while the legacy Ortho business experiences **1-1.5% pricing pressure** upon contract renewals [15][17] - Continuous improvement programs are in place to offset pricing erosion [17] Product Development and M&A - The decision to discontinue the Savanna product was driven by resource allocation towards the Rheonix product, which is expected to launch with FDA clearance by late 2025 or early 2026 [19][20] - The Rheonix product is anticipated to have competitive advantages in turnaround time and ease of use [21] Cross-Selling Opportunities - The integration of Quidel and Ortho has allowed for successful cross-selling, particularly with the Triage product, which has seen high single-digit growth due to the Ortho sales team [41][42] Future Outlook - For fiscal 2026, QuidelOrtho targets mid-single digit growth, with a **1-point headwind** from the donor screening business [43][45] - The Labs business is expected to maintain mid-single digit growth, while Immunohematology is projected to grow at **3-4%** [46][57] - The company aims for **100-200 basis points** of EBITDA margin improvement in 2026, driven by direct procurement initiatives [72][74] Cash Flow and Tariff Impact - The gross tariff impact for 2025 is estimated at **$20-25 million**, with potential reductions in 2026 depending on U.S.-U.K. tariff negotiations [65][66] - QuidelOrtho aims to achieve **50% free cash flow conversion** of adjusted EBITDA by the second half of 2027 [94][95] Conclusion - QuidelOrtho is navigating through various challenges, including revenue headwinds from donor screening and COVID declines, while focusing on margin improvements and product development. The company is optimistic about future growth and profitability, particularly with the anticipated launch of the Rheonix product and ongoing cost-saving initiatives.

Core Insights - QuidelOrtho Corporation, a leader in in vitro diagnostics, will participate in two upcoming investor conferences, enhancing its engagement with the investment community [1][5]. Company Overview - QuidelOrtho Corporation specializes in various diagnostic solutions, including clinical chemistry, immunoassay, immunohematology, and molecular testing, aimed at improving patient outcomes [3]. - The company is committed to advancing diagnostics to support a healthier future, reflecting its dedication to innovation and collaboration with healthcare providers [2][3]. Upcoming Events - Management will participate in the Evercore ISI 8th Annual Healthcare Conference on December 2, 2025, at 10:00 a.m. ET [5]. - Additionally, they will engage in the Citi Global Healthcare Conference on December 3, 2025, at 1:00 p.m. ET [5].

Core Insights - QuidelOrtho Corporation (QDEL) reported adjusted earnings per share (EPS) of 80 cents for Q3 2025, a decrease from 85 cents in the previous year, but exceeding the Zacks Consensus Estimate by 56.9% [1] - The company experienced a GAAP loss per share of $10.78, compared to a loss of 30 cents per share in the same quarter last year [1] Revenue Performance - QuidelOrtho's total revenues for Q3 2025 were $699.9 million, down 3.8% year-over-year on a reported basis and 4.6% at constant exchange rates (CER), but still above the Zacks Consensus Estimate by 5.3% [2] - Respiratory revenues fell to $112.3 million, a decline of 32.1% on a reported basis and 32.2% at CER, while Non-Respiratory revenues increased to $587.6 million, up 4.6% on a reported basis and 3.5% at CER [2] Business Unit Breakdown - QuidelOrtho's revenues are derived from five business units: Labs, Immunohematology, Donor Screening, Point of Care, and Molecular Diagnostics [3] - Labs revenues were $373.8 million, reflecting a 5% increase on a reported basis and 4.4% at CER [3] - Immunohematology revenues reached $142 million, up 7.7% on a reported basis and 5.2% at CER, while Donor Screening revenues dropped to $14.7 million, down 47.3% on a reported basis and at CER [4] - Point of Care revenues were $164.6 million, down 20% on a reported basis and 20.3% at CER, and Molecular Diagnostics revenues totaled $4.8 million, down 14.3% on a reported basis and 14.8% at CER [5][4] Geographical Revenue Distribution - North America revenues were $381.4 million, reflecting a decline of 12.6% on a reported basis and 12.5% at CER [6] - EMEA revenues increased to $91.8 million, up 9.3% on a reported basis and 2.4% at CER [6] - Revenues from China amounted to $84.6 million, reflecting a 5.2% increase on a reported basis and 4.8% at CER [7] - Other regions generated $142.1 million in revenues, up 12.3% on a reported basis and 12% at CER [9] Margin and Expense Analysis - Adjusted gross profit declined 4.6% year-over-year to $341 million, with an adjusted gross margin contracting 50 basis points to 48.7% [10] - Adjusted operating profit totaled $119.6 million, reflecting a 0.1% improvement from the prior-year quarter, with an adjusted operating margin expanding 70 basis points to 17.1% [11] Financial Position - QuidelOrtho ended Q3 2025 with cash and cash equivalents of $98.1 million, down from $151.7 million at the end of Q2 2025 [12] - Total debt at the end of Q3 2025 was $2.66 billion, compared to $2.61 billion at the end of Q2 2025 [12] - Cumulative net cash used in operating activities was $26.7 million, compared to net cash provided of $19.3 million a year ago [12] Guidance and Outlook - QuidelOrtho reiterated its financial outlook for 2025, projecting total revenues in the range of $2.68 billion to $2.74 billion, with the Zacks Consensus Estimate at $2.71 billion [13] - The company expects stable growth across most business lines, particularly in Labs and Immunohematology, with mid-single-digit growth anticipated in China [14] - For the full year, COVID-19 revenues are projected to be between $70 million and $100 million, with adjusted EPS expected to be between $2.00 and $2.15, compared to the Zacks Consensus Estimate of $2.28 [15] Overall Performance - QuidelOrtho's Q3 2025 results exceeded expectations, with both earnings and revenues beating the Zacks Consensus Estimate, driven by strong performance in Labs and Immunohematology [16] - However, the decline in respiratory revenues and decreases in Donor Screening, Point of Care, and Molecular Diagnostics units present challenges [17]